Alan Meds vs PlushCare
An in-depth comparison of two leading GLP-1 Providers
WeightLossRankings.org is reader-supported. When you buy through links on our site, we may earn an affiliate commission. Learn more
Alan Meds
Best for budget-conscious shoppersStarting at $99/mo
PlushCare
Best for readers who want a primary-care relationship with GLP-1 prescribing as one option, AND who read the class-action disclosure and verify the cancellation flow before subscribingStarting at $149/mo
Side-by-Side Comparison
| Feature | Alan Meds | PlushCare |
|---|---|---|
| Overall Score | ✓7.7/10 | 7.0/10 |
| Starting Price | ✓$99/mo | $149/mo |
| Editorial Rating | ✓3.9 ★ /5 | 3.5 ★ /5 |
| Features | 5 features | ✓7 features |
| States Available | 46 | ✓50 |
| Compounded | ✓ Yes | ✓ Yes |
| Brand Name | — | — |
| FSA/HSA Accepted | — | — |
| FDA Warnings | None | None |
Pros & Cons
Alan Meds
Pros
- ✓Aggressively low monthly pricing
- ✓Both semaglutide and tirzepatide available
- ✓Compounded GLP-1 access
- ✓Multiple administration formats
Cons
- ✗Limited public information on program details
PlushCare
Pros
- ✓All 50 states per the homepage
- ✓Appointments with US board-certified physicians (not nurse practitioners only)
- ✓Operates as virtual primary care, so the same provider can write GLP-1 prescriptions alongside other primary-care needs
- ✓Owned by Transcarent (post-Accolade-acquisition), a venture-backed health platform with named corporate parent
Cons
- ✗ACTIVE LITIGATION: California class action alleging deceptive subscription enrollment and unauthorized post-cancellation charges on the $19.99/month membership. Material disclosure for any reader signing up.
- ✗GLP-1 prescribing is clinician-discretionary at the visit level — not a guaranteed offering at intake
- ✗BBB rating reflects an ongoing pattern of complaints around the membership cancellation flow
Our Verdict
Alan Meds edges out PlushCare with a higher overall score of 7.7/10 and is particularly strong for budget-conscious shoppers. PlushCare remains a solid alternative, especially if you're looking for readers who want a primary-care relationship with GLP-1 prescribing as one option, AND who read the class-action disclosure and verify the cancellation flow before subscribing.
Wegovy®, Ozempic®, and Rybelsus® are trademarks of Novo Nordisk A/S. Mounjaro® and Zepbound® are trademarks of Eli Lilly and Company. All other product names and trademarks referenced on this page belong to their respective owners. WeightLossRankings.org is not affiliated with any pharmaceutical manufacturer. See trademark disclaimer.